Cancer drug interaction study completed in healthy volunteers
NCT ID NCT05906836
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This completed Phase 1 study looked at how a single dose of selpercatinib, a cancer drug, changes the amount of rosuvastatin (a cholesterol drug) in the blood. 28 healthy Caucasian adults took part. The goal was to see if there is a drug interaction and to check safety. Results will help guide future use of these medicines together.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Labcorp Clinical Research LP
Dallas, Texas, 75247, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selpercatinib and rosuvastatin
What this could lead to
If successful, this could help doctors understand how to safely combine selpercatinib with rosuvastatin or similar drugs.
What could go wrong
This is a very early, small study in healthy people, not patients. Results may not apply to real-world use or predict long-term safety.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.